Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751385 | 0.90 | MAPT (0.52) | MAPTALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL1751383 | 0.90 | MAPT (0.52) | MAPTALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL27178664 | 0.80 | HTR1A (0.56) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL1749412 | 0.80 | GFER (0.41) | MAPTALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL23983316 | 0.79 | SIRT6 (0.54) | MAPTALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL1749577 | 0.78 | MAPT (0.53) | MAPTALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL20610450 | 0.76 | MAPT (0.59) | MAPTALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL6710563 | 0.74 | MAPT (0.58) | MAPTALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL3549925 | 0.74 | MAPT (0.58) | MAPTALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL9969608 | 0.74 | MAPT (0.55) | MAPTALDH1A1SMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | MAPT 386/4885ALDH1A1 2558/4885SMN1; SMN2 1778/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | MAPT 512/4885ALDH1A1 2689/4885SMN1; SMN2 917/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | MAPT 512/4885ALDH1A1 2689/4885SMN1; SMN2 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.